A Phase l/ll Open-Label, Dose Escalation, Safety and Activity Study of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC)

Trial Profile

A Phase l/ll Open-Label, Dose Escalation, Safety and Activity Study of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs CDX 014 (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 14 Mar 2017 Celldex expects the Phase 1 dose-escalation portion of the study will complete enrollment by year-end 2017, as reported in a media release.
    • 15 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top